Cargando…

Selexipag for pulmonary arterial hypertension

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	NPS MedicineWise 2021
Materias:	New Drugs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075744/ https://www.ncbi.nlm.nih.gov/pubmed/33911339 http://dx.doi.org/10.18773/austprescr.2021.007

Ejemplares similares

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Use of selexipag in a teenage patient with pulmonary arterial hypertension
por: Bravo-Valenzuela, Nathalie Jeanne Magioli, et al.
Publicado: (2021)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
por: Hardin, Elizabeth Ashley, et al.
Publicado: (2016)

Baseline history of patients using selexipag for pulmonary arterial hypertension
por: Highland, Kristin B., et al.
Publicado: (2019)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension
por: Dong, Wenxing, et al.
Publicado: (2023)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

Sildenafil in pediatric pulmonary arterial hypertension
por: Dhariwal, AK, et al.
Publicado: (2015)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
por: Furukawa, Asuka, et al.
Publicado: (2017)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
por: Rothman, Abraham, et al.
Publicado: (2020)

Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension
por: Krause, A, et al.
Publicado: (2017)

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)

Systemic scleroderma-related interstitial pneumonia associated with borderline pulmonary arterial hypertension
por: Sugino, Keishi, et al.
Publicado: (2018)

Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients
por: Cui, Xiaopei, et al.
Publicado: (2022)

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
por: Alexandre, André, et al.
Publicado: (2023)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
por: Rosenkranz, Stephan, et al.
Publicado: (2021)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
por: Geerdink, Lianne M., et al.
Publicado: (2017)

Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series
por: Blissett, Sarah, et al.
Publicado: (2020)

Siponimod for multiple sclerosis
Publicado: (2021)

Cinnarizine/dimenhydrinate for vertigo
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Defibrotide for hepatic veno-occlusive disease
Publicado: (2021)

Ozanimod for multiple sclerosis
Publicado: (2021)

ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)

Trifarotene for acne
Publicado: (2021)

Tafamidis and tafamidis meglumine for amyloid cardiomyopathy
Publicado: (2021)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Recombinant varicella zoster virus glycoprotein E antigen vaccine for prevention of herpes zoster and postherpetic neuralgia
Publicado: (2021)

Trabectedin for soft tissue sarcoma
Publicado: (2021)

Sotrovimab for COVID-19
Publicado: (2021)

Elasomeran for prevention of COVID-19
Publicado: (2021)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Voretigene neparvovec for inherited retinal dystrophy
Publicado: (2021)

Lurbinectedin for small cell lung cancer
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gq5qcrh43fu3mhp613p005tsrd